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MEDICAL MARIJUANA POST-MCINTOSH
Robert L. Greenberg1
INTRODUCTION
On August 16, 2016, the United States Court of Appeals for the Ninth
Circuit issued a landmark decision on a series of cases relating to businesses
and individuals in the state-legal cannabis business. In United States v.
McIntosh,2 the Court heard ten cases challenging the United States
Department of Justice (DOJ) prosecution of medical marijuana patients.
These cases involved criminal defendants who were charged with violations
of federal narcotics laws while ostensibly in compliance with the laws of
their respective states.3 The court determined that federal law prohibits the
prosecution of these cases when the defendants are otherwise in compliance
with state law. The impact of this decision is discussed infra.
I.

THE UNDERLYING LAW

McIntosh deals with a unique interplay of conflicting statutes: the
Controlled Substances Act and the Continuing Appropriations Acts of 2015
and 2016. The former proscribes the possession, sale, and use of marijuana
in any form, and the latter prohibit the DOJ from interfering with state
medical marijuana laws.

1
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2
United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016).
3
The matter was “remand[ed] with instructions to conduct an evidentiary hearing to
determine whether Appellants have complied with state law.” Id. at 1179. No legal
determination was made regarding whether the defendants were in compliance with state
law. See generally id.
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A. The Controlled Substances Act
Marijuana—medical or otherwise—remains a Schedule 1 drug under
the Controlled Substances Act.4 Being listed as a Schedule 1 drug means
that there is no legitimate medical usage for marijuana.5The decision in
McIntosh does not affect the Controlled Substances Act. Further discussion
of this decision’s impact is found infra. However, several states have
enacted medical marijuana laws that license organizations to grow and
distribute cannabis products for limited medical purposes and license
patients to purchase and consume them. The state and federal laws come
into conflict in these states.
Previously, in Gonzales v. Raich, the United States Supreme Court
found that the states may not permit what federal law prohibits.6 What is
left is a statutory and regulatory scheme in which individuals and
organizations are in compliance with state law, but in violation of federal
law.
B. The Continuing Appropriations Acts
In 2014 and again in 2015, Congress passed Continuing Appropriations
Acts that contained a clause withholding funds from the DOJ in order to
prevent the DOJ from interfering with state medical marijuana laws. The
Court’s decision points to these Continuing Appropriations Acts of 2015
and 2016.7 The latter of these acts states:
None of the funds made available in this Act to the Department of Justice
may be used, with respect to any of the States of Alabama, Alaska,
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia,
Hawaii, Illinois, Iowa, Kentucky, Louisiana, Maine, Maryland,
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana,
Nevada, New Hampshire, New Jersey, New Mexico, New York, North
Carolina, Oklahoma, Oregon, Rhode Island, South Carolina, Tennessee,
Texas, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming,
or with respect to the District of Columbia, Guam, or Puerto Rico, to
prevent any of them from implementing their own laws that authorize the
use, distribution, possession, or cultivation of medical marijuana.8
4

21 U.S.C. § 812(c)(10) (2012).
Id. § 812(b)(1) (explaining that Schedule 1 drugs must have a “high potential for
abuse” and “a lack of accepted safety for use of the drug or other substance under medical
supervision”).
6
Gonzales v. Raich, 545 U.S. 1, 29 (2005) (“The Supremacy Clause unambiguously
provides that if there is any conflict between federal and state law, federal law shall
prevail.”).
7
McIntosh, 833 F.3d at 1169-70.
8
Consolidated Appropriations Act, 2016, Pub. L. No. 114-113, § 542, 129 Stat. 2242,
2332-33 (2015).
5
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These states and territories (together the “Medical Marijuana States”)9 have
already passed laws that authorize patients to receive medical marijuana as
a treatment for various ailments.In its operation, the Department of Justice
may not use the funds allocated to it to enforce the general prohibitions on
marijuana as a Schedule I Narcotic against those individuals in compliance
with state law.10
II.

CONGRESS’S “POWER OF THE PURSE” IN THE CONSTITUTION
A.

Defining Congress’s Check on the Executive Branch

Article I of the United States Constitution grants Congress the “power
of the purse.”11 The Constitution states, “No Money shall be drawn from the
Treasury, but in Consequence of Appropriations made by Law[.]”12 This
power means that no actions may be taken by the Executive without the
explicit approval of Congress. This clause is a basic example of checks-andbalances: without Congress approving the funds, the Executive Branch
cannot do anything.13
B.

Applying This Principle to the Department of Justice

The question before the Court was whether the Department of Justice
was drawing funds in violation of the Continuing Appropriations Acts.14
The language of the Acts was written only to prohibit the DOJ from
preventing “any of [the Medical Marijuana States] . . . from implementing
9

McIntosh, 833 F.3d at 1175, 1175 n.3. Since the elections on November 8, 2016, an
additional two states – Arkansas and North Dakota – will allow medical marijuana usage,
while three new states voted to legalize recreational marijuana use as well. See Christopher
Ingraham, Marijuana Wins Big on Election Night, WASH. POST (Nov. 8, 2016),
https://www.washingtonpost.com/news/wonk/wp/2016/11/08/medical-marijuana-sails-tovictory-in-florida [https://perma.cc/49F6-4M6H].
10
David Stout & Solomon Moore, U.S. Won’t Prosecute in States That Allow Medical
Marijuana,
N.Y.
TIMES
(Oct.
19,
2009),
http://www.nytimes.com/2009/10/20/us/20cannabis.html [https://perma.cc/EK77-A8KN].
11
See, e.g., Power of the Purse, U.S. HOUSE OF REPRESENTATIVES HISTORY, ART &
ARCHIVES,
http://history.house.gov/institution/origins-development/power-of-the-purse
[https://perma.cc/N2X3-EUPG] (last visited Aug. 30, 2016).
12
U.S. CONST. art. I, § 9, cl. 7.
13
See Office of Pers. Mgmt. v. Richmond, 496 U.S. 414, 424 (1990).
14
McIntosh, 833 F.3d at 1168 (“We are asked to decide whether criminal defendants
may avoid prosecution for various federal marijuana offenses on the basis of a
congressional appropriations rider that prohibits the United States Department of Justice
from spending funds to prevent states’ implementation of their own medical marijuana
laws.”).
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their own laws that authorize the use, distribution, possession, or cultivation
of medical marijuana.”15 The question then became: Does this prohibit the
DOJ from prosecuting individuals in these states who are in compliance
with their state laws?
The Court summarized the federal government’s arguments and
responded as follows:
DOJ argues that it does not prevent the Medical Marijuana States from
giving practical effect to their medical marijuana laws by prosecuting
private individuals, rather than taking legal action against the state. We are
not persuaded.
...
DOJ, without taking any legal action against the Medical Marijuana
States, prevents them from implementing their laws that authorize the use,
distribution, possession, or cultivation of medical marijuana by
prosecuting individuals for use, distribution, possession, or cultivation of
medical marijuana that is authorized by such laws. By officially permitting
certain conduct, state law provides for non-prosecution of individuals who
engage in such conduct. If the federal government prosecutes such
individuals, it has prevented the state from giving practical effect to its law
providing for non-prosecution of individuals who engage in the permitted
conduct.
We therefore conclude that, at a minimum, [the Continuing Appropriation
Act] prohibits DOJ from spending funds from relevant appropriations acts
for the prosecution of individuals who engaged in conduct permitted by
the State Medical Marijuana Laws and who fully complied with such laws.
16

The Court concluded that Congress forbade the DOJ from enforcing the
laws against individuals who are in compliance with state law. The DOJ
may not go after individuals who are in compliance.
III.

WHAT THIS DECISION MEANS

This decision is far reaching in its holding that enforcement of the
Controlled Substances Act is estopped in the Medical Marijuana States
when those who would be prosecuted are in compliance with their state
laws. Medical Marijuana businesses and individuals are safe from
prosecution as long as they maintain compliance with state medical
marijuana laws.

15

Consolidated Appropriations Act, 2016, Pub. L. No. 114-113, § 542, 129 Stat. 2242,
2332-33 (2015).
16
McIntosh, 833 F.3d at 1176-77 (emphasis added).
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Legality of Cannabis in These States

Federal law, namely the Controlled Substances Act, remains the law of
the land. As the McIntosh court explained, this decision does not change the
underlying prohibition of marijuana under federal law:
To be clear, [the Consolidated Appropriations Act] does not provide
immunity from prosecution for federal marijuana offenses. The
[Controlled Substances Act] prohibits the manufacture, distribution, and
possession of marijuana. Anyone in any state who possesses, distributes,
or manufactures marijuana for medical or recreational purposes (or
attempts or conspires to do so) is committing a federal crime. The federal
government can prosecute such offenses for up to five years after they
occur. Congress currently restricts the government from spending certain
funds to prosecute certain individuals. But Congress could restore funding
tomorrow[.] . . .
Nor does any state law ‘legalize’ possession, distribution, or manufacture
of marijuana. Under the Supremacy Clause of the Constitution, state laws
cannot permit what federal law prohibits. Thus, while the CSA remains in
effect, states cannot actually authorize the manufacture, distribution, or
possession of marijuana. Such activity remains prohibited by federal
law.17

The current act only prohibits the DOJ from using federal funding to go
after those in the Medical Marijuana States who are in compliance with
their state law. It does not change the underlying fact that these individuals
are not in compliance with federal law. Appropriation acts are temporary
measures and—as the court notes—the law could change tomorrow. It does
not discuss recreational marijuana, which is presumably still illegal after
this decision; the court only addresses how medical marijuana will not be
prosecuted. Medical Marijuana remains illegal under federal law, and will
remain so. The DOJ is enjoined from enforcing the Controlled Substances
Act with respect to marijuana, but this decision does not change the
underlying law.
B.

Federal Enforcement of the Law in Medical Marijuana States

This decision does not prohibit DOJ from enforcing federal law in these
Medical Marijuana States, and this decision does not protect individuals
who are not in compliance with state law. As the court explained,
“[i]ndividuals who do not strictly comply with all state-law conditions . . .
have engaged in conduct that is unauthorized, and prosecuting such
individuals” is legal.18 It is also important to note that this decision is very
17
18

Id. at 1179 n.5 (emphasis added) (internal citations omitted).
Id. at 1178.
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recent and the only one thus far that explicitly prohibits the federal
government from prosecuting legal medical marijuana users and businesses.
This decision does not affect the DOJ’s ability to prosecute recreational
marijuana users and businesses, even if they are in compliance with state
law. Even though the particular business may still be in compliance with
state law, since it is recreational and not medical, it is still violating the
federal Controlled Substances Act.19
C.

Impact of the Decision in Newer-Legalizing States

This recent decision has a far-reaching impact throughout the country.
The Ninth Circuit covers the western part of the United States,20 which has
largely lead the way in the legalization of medical marijuana (and also the
legalization of recreational marijuana). Subject to further appellate review
and a petition for certiorari, McIntosh is good law. This, in conjunction
with the Cole memorandum,21 should provide some safe harbor to those
individuals and businesses that are in the legal medical marijuana business
in the rest of the United States.
Maintaining compliance with state law is not an easy task, however. For
example, the New York Compassionate Care Act,22 which authorizes
medical marijuana, is still relatively new, with only five approved providers
in the state.23 Its rules are strict—including the prohibition of any
smokeable forms of marijuana.24 Patients cannot grow their own plants and
19

Id. at 1179 n.5.
U.S. COURTS, GEOGRAPHIC BOUNDARIES OF UNITED STATES COURTS OF APPEALS
AND UNITED STATES DISTRICT COURTS (2016), http://www.uscourts.gov/file/document/usfederal-courts-circuit-map [https://perma.cc/XG8X-M7X2].
21
Memorandum from James M. Cole, Deputy Att’y Gen., U.S. Dep’t of Justice, on
Guidance
Regarding
Marijuana
Enforcement
(Aug.
29,
2013),
https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
[https://perma.cc/NEU4-5BRH].
22
Assemb.
6357-E,
2013
Leg.,
237th
Sess.
(N.Y.
2014),
http://assembly.state.ny.us/leg/?term=2013&bn=A06357; see also New York State Medical
Marijuana
Program,
N.Y.
STATE
DEP’T
OF
HEALTH,
http://www.health.ny.gov/regulations/medical_marijuana [https://perma.cc/ZY55-TELU]
(last visited Aug. 24, 2016).
23
N.Y. STATE DEP’T OF HEALTH, MEDICAL USE OF MARIJUANA UNDER THE
COMPASSIONATE CARE ACT: TWO-YEAR REPORT 2-3 (2016) [hereinafter TWO-YEAR
REPORT],
http://www.health.ny.gov/regulations/medical_marijuana/docs/two_year_report.pdf
[https://perma.cc/UNE6-ZU73]; see also New York State Medical Marijuana Program:
Registered
Organizations,
N.Y.
STATE
DEP’T
OF
HEALTH,
http://www.health.ny.gov/regulations/medical_marijuana/application/selected_applicants.ht
m [https://perma.cc/GVK8-EFDL] (last visited Aug. 24, 2016).
24
TWO-YEAR REPORT, supra note 22, at 4 (“Smoking and edible products are not
20
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can only get their medical marijuana in limited doses and at registered
facilities.25 There have not been any determinations of compliance under
New York’s law yet.
Ultimately, this provides some comfort to those who are adhering to the
law and regulations promulgated by the states. As the state regulatory
schemes mature, it will become clear for those in the industry and their
patients how to maintain compliance and avoid federal prosecution.
***

permitted.”).
25
New York State Marijuana Program: Frequently Asked Questions, N.Y. STATE
DEP’T OF HEALTH, http://www.health.ny.gov/regulations/medical_marijuana/faq.htm
[https://perma.cc/DPV9-T8H5] (last visited Oct. 19, 2016).

